Risk of adverse birth outcomes after maternal varenicline use: A population-based observational study in Denmark and Sweden

Pharmacoepidemiology and Drug Safety

Volumn 29, Issue 1, 2020, Pages 94-102

  Pedersen, Lars ^a   Petronis, Kenneth R ^b   Nørgaard, Mette ^a   Mo, Jingping ^b   Frøslev, Trine ^a   Stephansson, Olof ^c   Granath, Fredrik ^c   Kieler, Helle ^c   Sørensen, Henrik Toft ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b PFIZER INC   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

observational study; pharmacoepidemiology; pregnancy outcome; varenicline

Indexed keywords

VARENICLINE;

ADULT; ADVERSE OUTCOME; ARTICLE; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; DENMARK; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MATERNAL EXPOSURE; MATERNAL SMOKING; OBSERVATIONAL STUDY; POPULATION RESEARCH; PREGNANCY OUTCOME; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMALL FOR DATE INFANT; STILLBIRTH; SUDDEN INFANT DEATH SYNDROME; SWEDEN; ADVERSE EVENT; DRUG SURVEILLANCE PROGRAM; MIDDLE AGED; MULTIPLE MALFORMATION SYNDROME; NEWBORN; PHARMACOEPIDEMIOLOGY; PREGNANCY; PRENATAL CARE; REGISTER; SMOKING; YOUNG ADULT;

ABNORMALITIES, MULTIPLE; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; DENMARK; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MATERNAL EXPOSURE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PREGNANCY; PRENATAL CARE; REGISTRIES; SMOKING; SMOKING CESSATION AGENTS; STILLBIRTH; SWEDEN; VARENICLINE; YOUNG ADULT;

EID: 85075054433     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.4894     Document Type: Article

References (24)

1. Källén K. The impact of maternal smoking during pregnancy on delivery outcome. Eur J Public Health. 2001;11(3):329-333.
2. Cnattingius S. The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine Tob Res. 2004;6(Suppl 2):S125-S140.
3. Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update. 2011;17(5):589-604.
4. Lee LJ, Lupo PJ. Maternal smoking during pregnancy and the risk of congenital heart defects in offspring: a systematic review and metaanalysis. Pediatr Cardol. 2013;34(2):398-407.
5. Committee on Health Care for Underserved Women. Smoking cessation during pregnancy. Obstet Gynecol. 2011;118:746-750.
6. Morales-Suárez-Varela MM, Bille C, Christensen C, Olsen J. Smoking habits, nicotine use and congenital malformations. Obstet Gynecol. 2006;107(1):51-57.
7. Wilcox A. Fertility and Pregnancy: An Epidemiologic Perspective. New York: Oxford University Press; 2010:324.
8. Coleman T, Cooper S, Thornton JG, et al. A randomized trial of nicotine-replacement therapy patches in pregnancy. N Engl J Med. 2012;366:808-818.
9. Chantix Prescribing Information. 2014; Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=557. Accessed 05/18, 2016.
10. Harrison-Woolrych M, Paterson H, Tan M. Exposure to the smoking cessation medicine varenicline during pregnancy: a prospective nationwide cohort study. Pharmacoepidemiol Drug Saf. 2013;22(10):1086-1092.
11. Richardson JL, Stephens S, Yates LM, et al. Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services. Reprod Toxicol. 2016;67:26-34.
12. Furu K, Wettermark B, Andersen M, Martikainen J, Almarsdottir A, Sørensen H. The Nordic Countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106(2):86-94.
13. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659-667.
14. Frank L. When an entire country is a cohort. Epidemiology. 2000;287:2398-2399.
15. Pottegård A, Schmidt SA, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798-798f.
16. Cnattingius S, Ericson A, Gunnarskog J, Kallen B. A quality study of a medical birth registry. Scand J Soc Med. 1990;18(2):143-148.
17. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull. 1998;45(3):320-323.
18. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490.
19. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009 July;20(4):512-522.
20. Ehrenstein V, Sorensen HT, Bakketeig LS, Pedersen L. Medical databases in studies of drug teratogenicity: methodological issues. Clin Epidemiol. 2010;2:37-43.
21. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320(7251):1708-1712.
22. Hawthorne G, Robson S, Ryall EA, Sen D, Roberts SH, Platt MW. Prospective population based survey of outcome of pregnancy in diabetic women: results of the northern diabetic pregnancy audit, 1994. BMJ. 1997;315:279-281.
23. Svensson E, Ehrenstein V, Nørgaard M, et al. Estimating the proportion of all observed birth defects occurring in pregnancies terminated by a second-trimester abortion. Epidemiology. 2014;25(6):866-871.
24. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397-2407.